Last reviewed · How we verify

NCT06571513

Written Exposure Therapy to Improve Recovery Among Sexual Assault Survivors

Completed NA Last updated 16 March 2026
What this trial tests

NA trial testing Written Exposure Therapy in Post-traumatic Stress Disorder in 30 participants. Completed in 7 March 2026.

Timeline
23 September 2024
Primary endpoint
7 March 2026
7 March 2026

Quick facts

Lead sponsorUniversity of North Carolina, Chapel Hill
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment30
Start date23 September 2024
Primary completion7 March 2026
Estimated completion7 March 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, female only, with Post-traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this pilot trial is to determine the feasibility and initial efficacy of telehealth-delivered written exposure therapy to reduce the development of posttraumatic stress disorder after sexual assault. This pilot trial will provide the data necessary to design and support a large-scale trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Written Exposure Therapy

Trials testing the same drug.

Other recruiting trials for Post-traumatic Stress Disorder

Currently open trials in the same condition.

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06571513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing